The UK and US have reached a important bilateral deal that will preserve zero levies on UK pharmaceutical exports being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to increase spending on drugs through the National Health Service (NHS). This move secures that import taxes on these vital exports will remain at nothing for a duration of the next three years.
This development follows recent statements to hike tariffs on patented drug imports, with potential rates mentioned as high as one hundred percent.
"This agreement with the UK strengthens the global environment for innovative medicines and brings much-needed balance to transatlantic pharmaceutical trade," a release noted.
Commercial Significance
Pharmaceuticals constitute one of the the United Kingdom's biggest exports to the United States, which is by far the largest buyer for major UK drugmakers.
Trade data show that in the 12 months to the end of the third quarter, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that span.
"This deal secures employment, stimulates investment and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary commented.
Key British Pledges
The deal entails several notable pledges from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to double total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must return to the NHS to prevent overspending will be limited at 15%. Last year, rebates topped twenty percent.
Recent Tensions
This agreement comes amid a protracted dispute between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
These tensions were heightened by assertions that American customers were paying a premium for the same drugs than patients in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial investments have been directed toward American operations.
One official acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.
